샘플 요청 목록

 카트 문의
시장보고서
상품코드
1742778

세계의 종양용해성 바이러스 요법 시장

Oncolytic Virus Therapy
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 483 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 종양용해성 바이러스 요법 시장은 2030년까지 4,520만 달러에 이를 전망

2024년에 1,380만 달러로 추정되는 종양용해성 바이러스 요법 세계 시장은 2030년에는 4,520만 달러에 이르고, 분석 기간인 2024-2030년 CAGR은 21.8%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 단순 헤르페스 바이러스는 20.8%CAGR을 기록해, 분석 기간 종료시에는 1,180만 달러에 이를 것으로 예측됩니다. 아데노바이러스 분야의 성장률은 분석 기간중 CAGR 19.2%로 추정됩니다.

미국 시장은 380만 달러로 추정, 중국은 CAGR 29.0%를 보일 것으로 예측

미국의 종양용해성 바이러스 요법 시장은 2024년에 380만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 29.0%로 성장을 지속하여 2030년에는 예측 시장 규모 1,070만 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 17.7%와 19.5%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 18.3%를 보일 전망입니다.

세계의 종양용해성 바이러스 요법 시장 - 주요 동향과 촉진요인 정리

유전자 재조합 바이러스가 암 면역치료의 다음 개척지가 될 수 있을까?

종양 용해성 바이러스 요법(OVT)은 유전자 조작 또는 자연적으로 존재하는 바이러스를 이용하여 정상 조직을 보존하면서 암세포를 선택적으로 감염시키고 파괴하는 암 치료의 최첨단 접근법입니다. 종양 내에 들어가면 바이러스는 복제되어 면역원성 세포 사멸을 유도하고 전신 항종양 면역반응을 자극합니다. 이러한 직접적인 세포 사멸과 면역 활성화라는 두 가지 작용기전으로 인해 OVT는 표적 치료와 면역 치료 사이의 유망한 가교 역할을 하며, 고형암과 혈액 악성 종양에 대한 적용이 기대되고 있습니다.

진행성 흑색종에 대한 HSV-1 기반 치료제인 Imlygic(Talimogene laherparepvec 또는 T-VEC)이 승인된 후, OVT에 대한 임상 및 전임상 관심이 급증했습니다. 이후 아데노바이러스, 레오바이러스, 백시니아바이러스, 홍역바이러스, 콕사키바이러스에 기반한 OVT 후보물질 파이프라인이 교모세포종, 췌장암, 대장암, 폐암 등 다양한 암 적응증에 대한 평가를 받고 있습니다. 합성생물학, 종양 표적 리간드, 면역조절 유전자 삽입의 발전은 온콜토바이러스의 특이성과 효능을 더욱 향상시켜 면역관문억제제, CAR-T 세포, 방사선 요법과의 이상적인 병용 파트너가 되고 있습니다.

병용요법 전략이 임상 상황을 변화시키는 이유는 무엇일까?

종양 용해성 바이러스의 단독 요법은 종양 유형에 따라 어느 정도 효과를 보이고 있습니다. OVT는 종양미세환경(TME)을 재프로그래밍하여 면역제거를 극복하고 T세포 침윤을 개선할 수 있으며, PD-1/PD-L1 체크포인트 억제제와 병용하면 시너지 효과를 얻을 수 있습니다. 현재 OVT를 항CTLA-4, CAR-NK 요법, 사이토카인 요법, 이중 특이성 항체, 특히 기존 IO 요법에 내성을 보이는 면역학적으로 "차가운" 종양에서 OVT를 평가하기 위한 여러 임상시험이 진행 중입니다.

이 분야의 중요한 트렌드는 사이토카인(GM-CSF, IL-12), 면역관문억제제 또는 종양 관련 항원을 암호화하는 도입 유전자를 발현하도록 OV를 공학적으로 설계하여 면역원성을 높인 다기능성 바이러스 치료제를 만드는 것입니다. 이러한 차세대 플랫폼은 반응률을 높일 뿐만 아니라 종양 특이적 선택성을 개선하고, 전신 독성을 감소시키며, 개인 맞춤형 치료 전략을 가능하게 합니다. 규제 환경이 개선되고 시험 설계의 적응성이 높아짐에 따라 OVT는 차세대 면역치료제 파이프라인의 핵심으로 점점 더 주목받고 있습니다.

기술 혁신과 배송 플랫폼은 어떻게 시장 도달 범위를 확장하고 있는가?

OVT 개발의 큰 과제 중 하나는 효율적인 전달과 면역 회피입니다. 종양 내 주입은 접근 가능한 병변에는 효과적이지만, 더 넓은 범위로의 적용에는 한계가 있습니다. 바이러스 차폐, 간엽줄기세포와 같은 운반세포를 이용한 전달, 나노입자 캡슐화 등 최근 전신 전달 방법의 발전은 중화항체 및 장기 특이적 봉쇄의 장벽을 극복하는 데 도움이 되고 있습니다. 이러한 전달 전략은 OVT를 전이성 및 심부 종양으로 확대하는 것을 목표로 하고 있습니다.

또한, CRISPR-Cas9와 같은 유전자 편집 도구는 더 나은 안전성, 종양 지향성, 페이로드 제어를 위해 바이러스 유전체을 미세 조정하는 데 사용되고 있습니다. 개발 기업들은 복제 동역학, 면역 활성화, 벡터 안정성을 최적화한 바이러스 변이체를 신속하게 설계하고 시험할 수 있는 모듈식 OVT 플랫폼을 개발하고 있습니다. 또한, AI 기반 약물 설계와 디지털 병리학을 통해 환자 계층화 및 예측 바이오마커 발견을 개선하여 정밀 종양학에서 OVT를 보다 타겟팅하고 효과적으로 활용할 수 있게 되었습니다.

종양용해성 바이러스 요법제 시장의 성장을 이끄는 요인은 무엇인가?

종양용해성 바이러스 요법 시장의 성장 원동력은 암 발병률 증가, 기존 치료법에 대한 내성 증가, OVT 메커니즘에 대한 임상적 검증이 확대되고 있습니다. 주요 성장 요인은 차세대 면역치료에 초점을 맞춘 바이오테크놀러지 기업, 제약사, 연구 컨소시엄의 투자 활성화입니다. 리프리뮨, 온콜틱스 바이오텍, 신라젠, CG종양, 로콘파마 등 OVT 플랫폼을 개발하는 기업들은 전략적 파트너십, 라이선싱 계약, 벤처캐피털의 자금이 투입되고 있습니다.

또한, 치료가 어려운 암에 대한 OVT 패스트트랙과 희귀질환치료제 지정이 인정되는 등 규제 당국의 기세도 높아지고 있습니다. 특히 북미, 유럽, 동아시아에서는 정부가 지원하는 암 퇴치 프로그램(moonshot program)과 산학협력이 시험 활동을 가속화하고 있습니다. 면역종양학, 바이러스학, 합성생물학이 융합되면서 1차 치료와 난치성 치료 모두에서 OVT의 길이 열리고 있으며, 선택의 폭이 제한된 환자들에게 새로운 희망을 주고 있습니다.

전달 시스템이 개선되고, 임상 데이터가 성숙해지고, 상업적 인프라가 강화됨에 따라 종양용해성 바이러스 요법는 틈새 실험적 치료법에서 주류 암 치료법으로 진화할 준비가 되어 있습니다. 국소적 종양 파괴와 전신적 면역 자극을 결합하는 독특한 능력을 가진 OVT는 종양학의 치료 패러다임을 재정의할 수 있는 잠재력을 가지고 있습니다.

부문

제품 유형(단순 포진 바이러스, 아데노바이러스, 백시니아 바이러스, 레오 바이러스, 홍역 바이러스, 기타 제품 유형), 용도(흑색종, 유방암, 두경부암, 방광암, 전립선암, 폐암, 기타 용도), 개발 단계(상업 단계, 파이프라인 단계), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 예(총 36개사)

  • Akamis Bio
  • Amgen Inc.
  • Calidi Biotherapeutics
  • Candel Therapeutics
  • CG Oncology
  • Genelux Corporation
  • Imugene Limited
  • Lokon Pharma AB
  • Oncolys BioPharma Inc.
  • Oncolytics Biotech Inc.
  • Replimune Group Inc.
  • SillaJen, Inc.
  • Theolytics Ltd.
  • Theriva Biologics
  • TILT Biotherapeutics Ltd.
  • Transgene S.A.
  • Turnstone Biologics Corp.
  • Valo Therapeutics Ltd.
  • VCN Biosciences S.L.
  • Vyriad, Inc.

관세 영향 계수

Global Industry Analysts는 본국, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 하락, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.18

Global Oncolytic Virus Therapy Market to Reach US$45.2 Million by 2030

The global market for Oncolytic Virus Therapy estimated at US$13.8 Million in the year 2024, is expected to reach US$45.2 Million by 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. Herpes Simplex Virus, one of the segments analyzed in the report, is expected to record a 20.8% CAGR and reach US$11.8 Million by the end of the analysis period. Growth in the Adenovirus segment is estimated at 19.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Million While China is Forecast to Grow at 29.0% CAGR

The Oncolytic Virus Therapy market in the U.S. is estimated at US$3.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.7 Million by the year 2030 trailing a CAGR of 29.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.7% and 19.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.3% CAGR.

Global Oncolytic Virus Therapy Market - Key Trends & Drivers Summarized

Could Engineered Viruses Become the Next Frontier in Cancer Immunotherapy?

Oncolytic virus therapy (OVT) represents a cutting-edge approach to cancer treatment that harnesses genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells while sparing normal tissues. Once inside the tumor, these viruses replicate, induce immunogenic cell death, and stimulate systemic anti-tumor immune responses-effectively turning the tumor into its own vaccine. This dual mechanism of action-direct oncolysis and immune activation-positions OVT as a promising bridge between targeted therapy and immunotherapy, with applications in solid tumors and hematologic malignancies.

Clinical and preclinical interest in OVT has surged following the regulatory approval of Imlygic (Talimogene laherparepvec or T-VEC), an HSV-1 based therapy for advanced melanoma. Since then, a growing pipeline of OVT candidates based on adenoviruses, reoviruses, vaccinia, measles, and coxsackieviruses is being evaluated across various cancer indications, including glioblastoma, pancreatic, colorectal, and lung cancers. Advances in synthetic biology, tumor-targeting ligands, and immune-modulatory gene insertion are further enhancing the specificity and potency of oncolytic viruses, making them ideal combination partners with immune checkpoint inhibitors, CAR-T cells, and radiotherapy.

Why Is Combination Therapy Strategy Transforming the Clinical Landscape?

Monotherapy with oncolytic viruses has shown modest efficacy in some tumor types; however, their greatest therapeutic potential is being realized in combination with other immuno-oncology (IO) agents. OVTs can reprogram the tumor microenvironment (TME), overcome immune exclusion, and improve T-cell infiltration-creating a synergistic effect when used alongside PD-1/PD-L1 checkpoint inhibitors. Multiple trials are currently underway to evaluate OVT in combination with anti-CTLA-4, CAR-NK therapies, cytokine therapies, and bispecific antibodies, especially in immunologically “cold” tumors that are resistant to existing IO regimens.

A key trend in the field is the engineering of OVs to express transgenes that encode for cytokines (GM-CSF, IL-12), immune checkpoint inhibitors, or tumor-associated antigens, creating multi-functional virotherapies with enhanced immunogenicity. These next-generation platforms are not only increasing response rates but also improving tumor-specific selectivity, reducing systemic toxicity, and enabling personalized medicine strategies. As the regulatory environment becomes more supportive and trial designs more adaptive, OVT is increasingly seen as a cornerstone of next-wave immunotherapy pipelines.

How Are Technological Innovations and Delivery Platforms Expanding Market Reach?

One of the major challenges in OVT development has been efficient delivery and immune evasion. Intratumoral injection, while effective for accessible lesions, limits broader applicability. Recent advances in systemic delivery methods-including virus shielding, carrier cell-based delivery (e.g., mesenchymal stem cells), and nanoparticle encapsulation-are helping overcome the barriers of neutralizing antibodies and organ-specific sequestration. These delivery strategies aim to extend OVT to metastatic and deep-seated tumors.

Moreover, gene editing tools such as CRISPR-Cas9 are being used to fine-tune viral genomes for better safety, tumor tropism, and payload control. Companies are developing modular OVT platforms capable of rapid design and testing of virus variants with optimized replication kinetics, immune activation, and vector stability. Additionally, AI-driven drug design and digital pathology are improving patient stratification and predictive biomarker discovery, enabling more targeted and effective use of OVT in precision oncology.

What’s Fueling the Growth of the Oncolytic Virus Therapy Market?

The growth in the oncolytic virus therapy market is driven by rising cancer incidence, increasing resistance to conventional therapies, and expanding clinical validation of OVT mechanisms. A primary growth driver is the intensifying investment by biotech companies, pharmaceutical giants, and research consortia focused on next-generation immunotherapies. Strategic partnerships, licensing deals, and venture capital funding are pouring into companies developing OVT platforms, including Replimune, Oncolytics Biotech, SillaJen, CG Oncology, and Lokon Pharma.

Additionally, regulatory momentum is building, with fast-track and orphan designations being granted for OVTs in hard-to-treat cancers. Government-backed cancer moonshot programs and academic-industry collaborations are accelerating trial activity, particularly in North America, Europe, and East Asia. The convergence of immune-oncology, virology, and synthetic biology is opening avenues for OVT in both first-line and refractory settings, offering new hope for patients with limited options.

As delivery systems improve, clinical data matures, and commercial infrastructure strengthens, oncolytic virus therapy is poised to evolve from a niche experimental modality into a mainstream cancer treatment. With its unique ability to combine localized tumor destruction and systemic immune stimulation, OVT holds the potential to redefine therapeutic paradigms in oncology.

SCOPE OF STUDY:

The report analyzes the Oncolytic Virus Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus, Other Product Types); Application (Melanoma, Breast Cancer, Head & Neck Cancer, Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications); Development Stage (Commercial, Pipeline Phase); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Akamis Bio
  • Amgen Inc.
  • Calidi Biotherapeutics
  • Candel Therapeutics
  • CG Oncology
  • Genelux Corporation
  • Imugene Limited
  • Lokon Pharma AB
  • Oncolys BioPharma Inc.
  • Oncolytics Biotech Inc.
  • Replimune Group Inc.
  • SillaJen, Inc.
  • Theolytics Ltd.
  • Theriva Biologics
  • TILT Biotherapeutics Ltd.
  • Transgene S.A.
  • Turnstone Biologics Corp.
  • Valo Therapeutics Ltd.
  • VCN Biosciences S.L.
  • Vyriad, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oncolytic Virus Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Emphasis on Precision Immuno-Oncology Therapies Drives Adoption of Oncolytic Virus Modalities
    • Expansion of Clinical Trials Across Multiple Tumor Types Throws the Spotlight on Versatile Oncolytic Platforms
    • OEM Innovation in Armed Oncolytic Vectors Strengthens Therapeutic Potency and Tumor Specificity
    • Regulatory Support for Breakthrough and Fast-Track Approvals Accelerates Time-to-Market for OV Candidates
    • Increased Collaboration Between Biotech Firms and Academic Research Centers Enhances Pipeline Diversity
    • Integration of Oncolytic Viruses With Checkpoint Inhibitors Supports Synergistic Immunotherapy Strategies
    • Growth in Intratumoral and Systemic Delivery Technologies Expands Treatable Cancer Sites
    • OEM Focus on Genetic Engineering of Viral Backbones Enhances Safety Profiles and Immune Stimulation
    • Emergence of Personalized Oncolytic Therapies Tailored to Tumor Microenvironments Expands Application Scope
    • Rising Investor Interest in Novel Modalities Spurs M&A Activity and Venture Capital Funding in OV Biotech
    • Use in Solid Tumors With Limited Therapeutic Options Strengthens Business Case in Unmet Needs Segment
    • Challenges in Anti-Viral Immune Response and Neutralization Drive Innovation in Shielding Technologies
    • Expansion of Viral Manufacturing Capabilities Supports Clinical and Commercial Scalability of OV Pipelines
    • OEM Partnerships With CDMOs and Viral Vector Platforms Enhance Process Development and GMP Readiness
    • Focus on Minimizing Off-Target Effects Propels Research Into Next-Gen Selective Viral Activation Mechanisms
    • Growing Interest in OV Therapies for Rare and Pediatric Tumors Opens Orphan Drug Development Pathways
    • Development of Biomarkers for Response Prediction Enhances Patient Selection and Trial Success
    • Global Support for Cancer Moonshot and Public Funding Initiatives Strengthens Basic OV Research Ecosystem
    • OEM Integration of Imaging and Companion Diagnostics Supports Monitoring and Combination Therapy Planning
    • Regulatory Harmonization Across U.S., EU, and Asia Facilitates Global Trial Expansion and Parallel Submissions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oncolytic Virus Therapy Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oncolytic Virus Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Adenovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Vaccinia Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Reovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Measles Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Measles Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Measles Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Head & Neck Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Pipeline Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Pipeline Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Pipeline Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 95: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Oncolytic Virus Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 122: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Italy 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 158: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: UK 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Spain 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Russia 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Australia 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Australia 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 233: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: India 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: India 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Oncolytic Virus Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 316: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 319: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Oncolytic Virus Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 343: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 346: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 355: Iran 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 358: Iran 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 367: Israel 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 370: Israel 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 391: UAE 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 394: UAE 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 415: Africa 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 418: Africa 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제